Clinical Guides
Leukaemia: Clinical Overview
A clinically focused, India-adapted overview of acute and chronic leukaemias, emphasizing immediate stabilisation, integrated lineage and genetic diagnosis, subtype-specific therapy and limits on cross-jurisdiction guidance.
MedNext Academy | 14 min read
Leukaemia: Clinical Overview
A clinically focused, India-adapted overview of acute and chronic leukaemias, emphasizing immediate stabilisation, integrated lineage and genetic diagnosis, subtype-specific therapy and limits on cross-jurisdiction guidance.
Summary
Leukaemia describes clonal malignant disorders centred on blood-forming tissues, but the label covers diseases with very different tempo, biology and treatment. The four broad teaching groups are acute myeloid leukaemia, acute lymphoblastic leukaemia, chronic myeloid leukaemia and chronic lymphocytic leukaemia. Modern classification then uses morphology, flow-cytometric immunophenotype, cytogenetics and molecular findings to define entities and therapeutic targets. A high white-cell count is neither required nor sufficient: acute leukaemia can present with pancytopenia and few circulating blasts, while reactive leucocytosis can be extreme without malignancy.
Acute leukaemia is a diagnostic and supportive-care emergency. Marrow failure causes infection, anaemia and bleeding; tissue infiltration and hyperleucocytosis may threaten organs. Suspected acute promyelocytic leukaemia is especially time critical because disseminated coagulopathy and early haemorrhage can be fatal. Chronic leukaemias may be discovered incidentally, yet accelerated CML, symptomatic progressive CLL or transformation also requires rapid specialist care. The first safe action is not to name a chemotherapy combination. It is to assess physiological danger, contact haematology, preserve diagnostic specimens and initiate protocolled supportive treatment.
Definitive care depends on the exact disease, age, fitness, organ function, pregnancy, infection, genomic risk, measurable residual disease, donor options, treatment access and patient priorities. Therapy may include cytotoxic chemotherapy, differentiation treatment, kinase inhibition, antibodies, other targeted agents, immunotherapy or allogeneic transplantation. Some CLL needs observation rather than immediate treatment. Every pathway requires transfusion, infection, tumour-lysis, fertility and psychosocial planning. This guide teaches cross-cutting reasoning only and remains reviewed and has been reviewed by the MedNext Clinical Team.
How Common Is It?
Leukaemia frequency changes sharply with age and subtype. Acute lymphoblastic leukaemia is the predominant childhood leukaemia, while acute myeloid leukaemia becomes more common with advancing adult age. CLL is principally a disease of older adults and is recorded less often in many Asian populations than in Western registries. CML can occur across adulthood and occasionally in children. These patterns are useful for probability but do not exclude any type outside its usual age range.
India does not have one complete real-time national leukaemia registry. The ICMR-NCDIR National Cancer Registry Programme report collates defined population-based registries whose coverage, age structure, urban-rural mix and diagnostic capacity vary. Hospital registries describe people reaching participating centres and cannot supply community incidence. Childhood cases may be recorded through different systems from adult disease. A national projection for all cancers should not be reverse-engineered into a precise leukaemia count without the appropriate table and denominator.
Diagnostic capacity changes apparent burden. Access to a reliable blood count may detect chronic disease incidentally; access to marrow morphology, flow cytometry and molecular testing determines whether an undifferentiated acute leukaemia receives a precise entity. Early deaths before referral may be underrepresented. Migration to tertiary centres can inflate local hospital proportions. International PDQ summaries quote United States incidence and outcomes and must not be presented as Indian statistics. Survival also varies by subtype, molecular risk, age, infection, treatment completion and access; a single ‘leukaemia survival rate’ is misleading. For individual care, unusual bruising, fever, pallor, persistent blood-count abnormalities or blasts justify evaluation regardless of recorded regional frequency, while an isolated mild count deviation more often has a non-malignant cause and should be interpreted in context.
Risk Factors
Most leukaemia is not explained by one behaviour, and patients should not be blamed. Increasing age raises the risk of many myeloid and lymphoid neoplasms. Certain constitutional syndromes, including Down syndrome and inherited marrow-failure or DNA-repair disorders, predispose to defined childhood or adult entities. A detailed family history matters when several relatives have cytopenias, myeloid neoplasms or early cancers, but routine molecular screening of every healthy relative is not justified. Germline evaluation is specialist-led because results affect donor selection and family counselling.
Previous cytotoxic chemotherapy or radiotherapy can cause therapy-related myeloid neoplasia after a variable latency. Benzene exposure is an established myeloid risk, whereas most everyday chemical exposures are too nonspecific to attribute causation in an individual. Tobacco contributes to AML risk and broader harm. Prior myelodysplastic syndrome or a myeloproliferative neoplasm can evolve to AML. CML is defined by BCR::ABL1 rather than by a lifestyle exposure. CLL risk has familial and population patterns, but no preventive screening test is recommended for asymptomatic relatives.
Viral causes are entity-specific: human T-cell lymphotropic virus type 1 is associated with adult T-cell leukaemia/lymphoma in endemic populations. Infection more often complicates leukaemia than causes it. Immunosuppression can change lymphoid malignancy risk but does not explain most acute leukaemia. In children, ionizing radiation and rare genetic predispositions matter, yet parental actions are rarely responsible. Ask about prior cancer treatment, occupational exposure, antecedent blood disorder, infections, medicines and family history. These details guide classification, genetics and counselling; they do not replace blood film, marrow and molecular testing. No diet, vitamin, detoxification programme or commercial blood panel has been shown to prevent the major leukaemia subtypes.
Diagnosis
History
Establish tempo: days to weeks favours acute marrow failure, while chronic disease may be incidental or slowly symptomatic. Ask about fever, recurrent infection, fatigue, dyspnoea, palpitations, bruising, petechiae, epistaxis, gum bleeding, heavy menstrual bleeding, weight loss, night sweats, bone pain, abdominal fullness, early satiety, headache, confusion, visual change and priapism. Record previous counts, transfusions, cancer therapy, cytotoxic exposure, pregnancy, medicines, immune status and family history. Clarify recent steroids because they can alter lymphoblast assessment.
Examination
Assess airway, breathing, circulation, mental state, fever and active bleeding first. Look for pallor, petechiae, purpura, ecchymosis, retinal or mucosal haemorrhage, gingival enlargement, lymphadenopathy, sternal tenderness, hepatosplenomegaly, skin infiltrates and infection. Examine cardiorespiratory status for leucostasis or severe anaemia and perform focused neurology and fundus assessment when symptoms warrant. Testicular enlargement or focal neurological findings can represent sanctuary-site disease in ALL. Absence of nodes or splenomegaly does not exclude acute leukaemia.
Investigations
Repeat complete blood count with differential and urgent expert blood-film review; obtain coagulation studies, fibrinogen, renal and liver profiles, electrolytes, calcium, phosphate, urate, lactate dehydrogenase, cultures and infection tests according to presentation. Contact haematology immediately if blasts, pancytopenia with illness, hyperleucocytosis or suspected APL appears. Bone-marrow aspirate and trephine usually establish morphology and provide flow, cytogenetic and molecular material; blood may suffice for selected tests when circulating disease is abundant. Diagnose CML by demonstrating BCR::ABL1. In an adult, CLL generally requires at least 5 × 10^9 per litre clonal B lymphocytes in peripheral blood for at least three months, with the characteristic phenotype; lower counts without tissue disease may represent monoclonal B-cell lymphocytosis. An integrated report must reconcile all modalities. Cerebrospinal fluid assessment is performed only through the disease protocol and is unsafe during uncontrolled coagulopathy.
Differential Diagnosis
Sepsis, acute viral infection, severe inflammation, corticosteroids and physiological stress can produce leucocytosis, sometimes with immature myeloid cells. A leukemoid reaction remains polyclonal and should resolve with its cause; basophilia, splenomegaly and BCR::ABL1 support CML but no single routine count proves it. Pertussis can cause striking lymphocytosis. Epstein-Barr virus, cytomegalovirus and other infections generate atypical lymphocytes that may resemble blasts to an inexperienced observer. Expert film review and flow cytometry resolve uncertainty.
Pancytopenia has many alternatives: aplastic anaemia, megaloblastic deficiency, severe infection, hypersplenism, autoimmune disease, haemophagocytic lymphohistiocytosis, marrow infiltration by lymphoma or solid cancer, myelofibrosis and drug toxicity. Myelodysplastic neoplasms produce cytopenia and dysplasia and may progress to AML. Paroxysmal nocturnal haemoglobinuria and immune destruction require different testing. An isolated thrombocytopenia should not automatically be labelled immune thrombocytopenia when anaemia, neutropenia, blasts, organomegaly or systemic illness is present.
Acute leukaemia lineage cannot be assigned reliably from morphology alone. AML, B-ALL, T-ALL, mixed-phenotype acute leukaemia, blast-phase CML and marrow involvement by high-grade lymphoma have overlapping presentations. In children, marrow metastasis from neuroblastoma or other solid tumours is uncommon but important. CLL must be distinguished from monoclonal B-cell lymphocytosis, mantle-cell lymphoma with circulating cells and other mature B-cell neoplasms. Reactive lymphocytosis is usually transient and polyclonal. Leucoerythroblastic films may reflect marrow infiltration or severe stress rather than leukaemia. If laboratory, clinical and genetic results disagree, pause for integrated haematopathology review instead of forcing a familiar label or beginning subtype-specific therapy from one marker.
Management
Stabilisation and diagnosis proceed together. Treat sepsis, haemorrhage, symptomatic anaemia, metabolic disturbance and organ compromise through local emergency and haematology protocols while preserving specimens. Hyperleucocytosis management depends on symptoms and disease; the count alone does not define leucostasis. When APL is suspected, obtain time-critical molecular samples, involve senior haematology immediately and start all-trans retinoic acid under the emergency protocol without waiting for confirmation, while aggressively supporting the coagulopathy. Tumour-lysis risk is assessed before cytoreduction. Use irradiated, leukoreduced or specially selected blood components when the disease and future transplant pathway require them.
AML management integrates fitness, cytogenetic and molecular risk, measurable residual disease, targetable lesions and transplant candidacy. APL follows a distinct differentiation-based pathway. ALL treatment is multiphase and includes central nervous system-directed therapy; paediatric and adolescent protocols differ from older-adult care. CML is generally treated with a BCR::ABL1 tyrosine-kinase inhibitor and monitored by standardized quantitative molecular testing, with response milestones informing mutation analysis, adherence review, drug change or transplant consideration. CLL without active symptoms or threatened marrow/organ function often undergoes observation; when treatment is indicated, molecular risk, comorbidity and current targeted-agent evidence guide selection.
Allogeneic transplantation is potentially curative for selected high-risk or relapsed diseases but carries graft-versus-host disease, infection, infertility and organ toxicity. Relapse care may include re-induction, targeted agents, antibody therapy, cellular immunotherapy, donor strategies or clinical trials according to subtype. Supportive care includes antimicrobial prevention, safe transfusion, nutrition, oral care, menstrual management, fertility preservation, venous-access planning, rehabilitation and psychological support. Palliative care is active symptom and decision support at any stage. Every patient needs an explicit response-monitoring method; marrow remission, measurable residual disease and molecular response are not interchangeable endpoints.
Prescribing Information
Leukaemia medicines must be prescribed through a verified disease protocol by a trained team with pharmacy support. Before treatment, confirm the integrated diagnosis, age and protocol group, body size, pregnancy status, fertility discussion, organ function, infection screen, ECG or cardiac assessment where relevant, interactions and central-line plan. Treatment doses and schedules differ even when the same agent appears in AML, ALL, CML or CLL. Never reconstruct a regimen from abbreviations or an educational summary.
Myelosuppressive therapy can cause prolonged neutropenia, mucositis, sepsis, bleeding and transfusion dependence. Cytarabine, anthracyclines, asparaginase, methotrexate, cyclophosphamide and corticosteroids have distinct neurological, cardiac, hepatic, thrombotic, metabolic and infection toxicities. Intrathecal medicines require independent checking; vincristine must never enter the intrathecal route. Differentiation treatment for APL can cause differentiation syndrome, while arsenic trioxide requires electrolyte and QT monitoring. Tyrosine-kinase inhibitors differ in cardiovascular, pulmonary, hepatic, pancreatic and interaction profiles; adherence and molecular response must be reviewed before assuming resistance. Targeted CLL medicines can produce bleeding, arrhythmia, infection, cytopenia or tumour lysis depending on agent.
Tumour-lysis prevention is risk based and may require monitored hydration, allopurinol or rasburicase, frequent chemistry and rapid renal support. Antimicrobial prophylaxis, growth factors and immunoglobulin are not universal and follow regimen and immune risk. Screen for hepatitis B before relevant antibody therapy. Review azoles, antituberculous medicines, anticonvulsants, herbal products and grapefruit-type interactions with kinase inhibitors. Verify Indian approval, formulary and current institutional guidance; an FDA or UK authorization is not automatically applicable. Give written fever and bleeding thresholds, an around-the-clock contact route, transfusion instructions and missed-dose advice. Avoid rectal procedures and intramuscular injections during profound cytopenia unless specifically justified.
When to Refer
Any suspected acute leukaemia needs same-day discussion with haematology, even if the patient appears well. Triggers include circulating blasts, unexplained pancytopenia or bicytopenia, severe neutropenia with fever, coagulopathy, rapidly worsening counts, hyperleucocytosis, tumour-lysis chemistry or a clinical picture strongly suggestive of marrow failure. Send the blood-count trend and film images where possible, but do not delay transfer for nonessential tests. A patient with active bleeding, sepsis, respiratory or neurological symptoms belongs in emergency care with simultaneous specialist contact.
Persistent unexplained leucocytosis, basophilia, monocytosis or lymphocytosis also requires haematology evaluation, with urgency based on symptoms, trajectory and associated cytopenias or organomegaly. Suspected CML needs BCR::ABL1 testing and a monitoring-capable service. A clonal B-cell lymphocytosis requires distinction between monoclonal B-cell lymphocytosis and CLL and should not receive treatment simply because a clone exists. Children and adolescents must be referred to paediatric or age-appropriate haemato-oncology; pregnancy requires joint maternal-fetal and haematology planning.
After diagnosis, involve transplantation early when risk may make donor search or fertility preservation time sensitive. Add infectious diseases for complex infection, nephrology for severe tumour lysis, intensive care for organ failure, neurology for central nervous system involvement and transfusion medicine for antibodies or special-component needs. Genetics is important when germline predisposition is suspected because a related donor may carry the same variant. In India, a usable referral includes stability, recent transfusions and steroids, all reports, preserved marrow or blood material, infection results, financial and travel constraints, and direct acceptance by the receiving centre. Advise the family not to seek multiple uncoordinated empirical treatments while a time-critical diagnosis remains unresolved.
Red Flags
Suspected APL with bleeding, petechiae, low fibrinogen, prolonged coagulation tests or schistocytes is an immediate haemato-oncology emergency because intracranial and pulmonary haemorrhage can occur early. Do not wait for a routine marrow appointment. Fever with neutropenia, hypotension, rigors, confusion or respiratory compromise requires sepsis treatment according to local policy after cultures when this does not delay antibiotics. Active mucosal, gastrointestinal, intracranial or postpartum bleeding needs urgent transfusion-medicine and haematology support.
Hyperleucocytosis with dyspnoea, hypoxia, headache, confusion, focal deficit, visual disturbance, priapism or renal injury may represent leucostasis. The absolute count threshold differs by lineage, so symptoms and disease matter. Avoid routine red-cell transfusion before specialist discussion in severe hyperviscosity because viscosity may worsen, unless life-threatening anaemia demands a controlled approach. Tumour lysis is signalled by potassium, phosphate and urate elevation, calcium reduction, arrhythmia, seizure, oliguria or rising creatinine and can arise before therapy.
Severe bone pain with neurological change, testicular swelling, cranial-nerve findings or altered consciousness may indicate extramedullary or central nervous system involvement. CML blast transformation can present with rapidly rising counts, cytopenias, fever, bone pain and splenic enlargement. In CLL, sudden node growth, fever, weight loss and lactate dehydrogenase rise may suggest Richter transformation but require biopsy. During treatment, chest pain, severe headache, pancreatitis symptoms, jaundice, dyspnoea, uncontrolled diarrhoea, inability to drink or new rash can signal life-threatening toxicity. Stabilise first, notify haematology early and record time-critical interventions. Red flags establish urgency, not the final subtype.
Indian Clinical Context
Indian leukaemia care spans highly specialised transplant centres and districts with limited flow cytometry, molecular testing, blood components or infection isolation. The ICMR immunophenotyping SOP was developed to reduce laboratory variability in sample collection, transport, processing, panel design, reporting and quality control. It remains a valuable local process reference but dates from 2016 and explicitly anticipates revision. Current classifications and molecular treatment markers must therefore be reconciled through experienced integrated reporting rather than a historic antibody panel alone.
Specimen logistics are clinical care. Bone marrow or blood delayed in heat, sent in the wrong anticoagulant or exhausted by serial testing can prevent lineage and genetic definition. Contact the reference laboratory before collection, label transfusion and steroid history, and send viable material by an agreed route. If a test is unaffordable or unavailable, document the resulting uncertainty and whether referral would change treatment. Empirical antituberculous therapy or corticosteroids for fever, nodes or cytopenia can obscure the diagnosis and create interactions once leukaemia treatment begins.
current guidelines describes UK integrated diagnostics, staffing and facilities for intensive chemotherapy; it is a service benchmark, not an Indian commissioning rule. NCI PDQ summaries are current evidence syntheses, not United States policy and not Indian protocols. Drug licensing, antimicrobial resistance, blood supply, intensive-care support and transplant access differ. Financial toxicity, travel, temporary accommodation and caregiver income can determine whether prolonged induction is feasible. Discuss these constraints early without overstating equivalence between regimens. Link eligible children to public and charitable support pathways where available. Consent in the preferred language should cover infertility, infection, transfusion, prolonged admission, relapse uncertainty and late effects. No universal Indian survival figure or uniformly available molecular panel is claimed.
NMC Competency Mapping
NMC CBME Curriculum 2024 PA18.1 requires learners to distinguish causes of leucocytosis, leucopenia, lymphocytosis and leukemoid reactions. PA18.2 directly covers the aetiology, genetics, pathogenesis, classification, clinical and haematological features of acute and chronic leukaemia. General cancer outcomes PA6.1 to PA6.5 add neoplasia, molecular carcinogenesis, spread, host effects and laboratory diagnosis. PA20.2 on disseminated intravascular coagulation supports recognition of the APL emergency, while blood-bank competencies PA21.1 to PA21.6 supply transfusion foundations.
An undergraduate should identify marrow-failure patterns, assess sepsis and bleeding, request a complete count and expert film, and recognise blasts as an emergency finding rather than assign lineage from appearance. They should compare acute with chronic tempo; myeloid with lymphoid principles; reactive leucocytosis with CML; and monoclonal B-cell lymphocytosis with symptomatic CLL at an introductory level. They should explain how morphology, flow, cytogenetics and molecular tests create an integrated diagnosis and why BCR::ABL1 is central to CML.
Teaching should integrate pathology, medicine, paediatrics, pharmacology, microbiology, transfusion medicine and genetics. Suitable assessments include an unwell patient with pancytopenia, an APL coagulopathy, hyperleucocytosis with neurology or an incidental lymphocytosis requiring measured evaluation. Students should state initial stabilisation, specimen preservation and referral rather than independently choose chemotherapy. They should understand remission, measurable residual disease and molecular monitoring as different concepts. Curriculum coverage does not certify marrow aspiration, flow interpretation, intrathecal administration, systemic anticancer prescribing or transplant selection; each is supervised and protocol-bound. Current regimens evolve too quickly to be reduced to one memorised list.
Key Exam Pearls for NEET PG
Acute leukaemia presents through marrow failure: anaemia, infection and bleeding, with or without circulating blasts or leucocytosis. AML is predominantly myeloid and commoner with older age; ALL is the commonest childhood leukaemia but occurs in adults. Auer rods support myeloid differentiation; bundles of rods suggest APL, where t(15;17) creates PML::RARA. Suspected APL with coagulopathy is a treatment emergency. TdT is a marker of immaturity in most ALL, not a universal leukaemia marker.
CML is a myeloproliferative neoplasm defined by BCR::ABL1, classically from t(9;22), with granulocytic proliferation, basophilia and splenomegaly. Quantitative BCR::ABL1 monitoring assesses tyrosine-kinase inhibitor response. A leukemoid reaction is reactive and lacks the defining fusion. CLL is a mature clonal B-cell disease; smudge cells are a film association, not enough for diagnosis. Asymptomatic early CLL is commonly observed, while progressive marrow failure, bulky disease or constitutional symptoms can trigger treatment.
Flow cytometry establishes lineage and maturity; cytogenetic and molecular results refine entity, risk and targets. Bone marrow supplies morphology and ancillary testing, but urgent blood testing is valuable when blasts circulate. Hyperleucocytosis can cause leucostasis, especially in AML; clinical symptoms matter more than one threshold. Tumour lysis may be spontaneous. Neutropenic fever, severe bleeding and metabolic disturbance are emergencies. Avoid intramuscular injections and rectal procedures in profound cytopenia. Vincristine is fatal if given intrathecally. For NMC remember PA18.1 for reactive count disorders, PA18.2 for acute and chronic leukaemia, PA20.2 for DIC and PA21 for transfusion principles.
Frequently Asked Questions
Can a normal or low white-cell count rule out acute leukaemia?
No. Acute leukaemia can present with pancytopenia, a normal total count or few detectable circulating blasts because the malignant population is concentrated in marrow. Symptoms, the differential count and expert blood-film review matter. An unwell patient with unexplained bicytopenia or pancytopenia needs urgent assessment even when the total white-cell number is not high.
Why are flow cytometry and molecular tests needed after blasts are seen?
Blasts confirm neither lineage nor the full disease entity. Flow cytometry defines lineage and maturation, while cytogenetic and molecular tests identify defining abnormalities, risk groups and therapeutic targets. These data must be integrated with morphology and the clinical picture. Starting subtype-specific treatment from one marker can be unsafe, except where an emergency pathway such as suspected APL requires immediate specialist action.
Does every person diagnosed with chronic lymphocytic leukaemia require immediate treatment?
No. Many people with asymptomatic early CLL are observed because immediate treatment may add toxicity without benefit. Treatment is considered when there is progressive marrow failure, symptomatic or threatening organ and node enlargement, significant constitutional symptoms or other accepted activity criteria. Observation still requires scheduled review, infection and vaccination advice, and a route for rapid reassessment.
Can an international leukaemia treatment summary be used as an Indian prescribing protocol?
No. International summaries can explain evidence and broad principles, but exact diagnosis, medicine approval, infection patterns, blood support, monitoring, intensive care and affordability differ. Indian regulatory status, an institutional haemato-oncology protocol, specialist pharmacy checking and patient-specific organ function must govern prescribing. Older Indian guidance also needs reconciliation with current classification and molecular evidence.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic